iCliniq Logo
HomeAnswersInternal Medicinelung cancer

Why did stage 4 ALK cancer not respond to immunotherapy?

This Premium Q&A, reviewed and published, features a real conversation between an iCliniq user and a physician.

Patient's Query

Hello doctor,

My brother is 38 and has stage 4 ALK-positive lung cancer. Initially, doctors tried immunotherapy, but scans after three cycles showed progression. Later, a mutation test was done. We were confused as to why the treatment failed. We are looking for your opinions on the following:

  1. Why did stage 4 ALK cancer not respond to immunotherapy?

  2. Does ALK mutation make immunotherapy ineffective?

  3. Would targeted therapy have been a better first option?

  4. Also, does a poor response to immunotherapy mean prognosis is worse, or does switching treatment change the outlook significantly?

Kindly give your suggestions.

Thank you.

Hello,

Welcome to icliniq.com.

I have read your query and understand your concern.

In ALK (anaplastic lymphoma kinase)-positive lung cancer, immunotherapy often does not work well. This is because these tumors usually have biological features (like low mutation burden) that make them less visible to the immune system.

So, disease progression after a few cycles of immunotherapy is common in ALK-positive patients and does not mean something unusual or wrong happened. The ALK mutation itself is a strong “driver” of the cancer, and treatments that directly target this mutation (ALK inhibitors) are much more effective than immunotherapy in most cases.

Because of this, targeted therapy is generally the preferred first-line treatment once ALK positivity is known. In some situations, treatment like immunotherapy or chemotherapy is started first because of the following reasons:

  1. Mutation results like NGS (next-generation sequencing) are not yet available.

  2. The cancer needs urgent treatment.

  3. The ALK status was unknown initially.

Once the mutation is identified, doctors usually switch to targeted therapy, which is what should happen. Importantly, poor response to immunotherapy does not mean a worse prognosis in ALK-positive lung cancer. It is an expected behavior for this cancer subtype.

I hope you find this information helpful.

For more queries, feel free to reach out to me anytime.

Thank you.

Medically reviewed byiCliniq medical review team

Published At March 27, 2026
Reviewed AtMarch 27, 2026

Same symptoms don't mean you have the same problem. Consult a doctor now!

Listen to related tracks in our music library

Ask your health query to a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.